NCT07042139: DISCLOSE

No Reduction Compared to Closed Reduction for Distal Radius Fractures in Patients Over 65 or Older

Recruiting now NA Last updated 21 January 2026

What this trial tests

NA trial testing No reduction in Distal Radius Fracture in 532 participants. Currently enrolling.

Timeline

1 August 2025

Primary endpoint
1 July 2029

1 July 2033

Quick facts

Lead sponsor	Tampere University Hospital
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	532
Start date	1 August 2025
Primary completion	1 July 2029
Estimated completion	1 July 2033
Sites	10 locations across Finland, Denmark, Estonia, Sweden

Drugs / interventions tested

• No reduction
• Closed Reduction
• Casting

Conditions studied

• Distal Radius Fracture — all drugs for Distal Radius Fracture →
• Casting — all drugs for Casting →
• Closed Reduction — all drugs for Closed Reduction →

Sponsor

Tampere University Hospital

Who can join

65 and older, any sex, with Distal Radius Fracture or Casting. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

DISCLOSE trial is a randomized controlled trial including 532 participants with low-energy distal radius fractures. The primary objective is to evaluate whether casting without prior closed reduction is equivalent to casting following closed reduction with respect to wrist-related pain and disability, as measured by the Patient-Rated Wrist Evaluation (PRWE) score at 12 months, in patients aged 65 years or older with a displaced distal radius fracture.

* Primary endpoint will be PRWE at 12 months
* Follow-up visits are scheduled at 3 and 12 months. 5-year follow-up will be considered as an exploratory endpoint

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Effect of no reduction versus closed reduction on distal radius fractures in adults aged 65 years and older: a protocol for the DISCLOSE randomised equivalence trial.
   Kärnä L, Ponkilainen V, Reito A, Østergaard H, et al · · 2025 · PMID 41101953 · DOI 10.1136/bmjopen-2025-108511